The company is already renowned by many as a giant in the segment.

AbbVie Inc. (NYSE:ABBV) is one of the top trending US stocks to buy now. AbbVie Inc. (NYSE:ABBV) and Apogee Therapeutics ...

The cash deal will add an experimental drug for moderate to severe atopic dermatitis, building up AbbVie’s core business.

AbbVie’s largest deal in more than half a decade adds a group of immune disease medications — among them a Dupixent ...

By Padmanabhan Ananthan June 22 (Reuters) - AbbVie said on Monday it would buy Apogee Therapeutics for $10.9 billion, the ...

AbbVie is buying Apogee Therapeutics, the developer of an experimental atopic dermatitis drug, for nearly $11B, continuing a ...

June 19 (Reuters) - AbbVie is nearing a deal to acquire inflammatory disease drug developer Apogee Therapeutics for about $10 ...

Welcome to the Apogee Enterprises First Quarter Earnings Conference Call. At this time, participants are in a listen-only ...

AbbVie has struck a deal to buy Apogee Therapeutics for $10.9 b | AbbVie has struck a deal to buy Apogee Therapeutics for $10 ...

The pharmaceutical company gains a prospective blockbuster with the deal, but is it worth $10.9 billion?

Apogee Therapeutics is being acquired by AbbVie for $135.11 per share in cash, capping further upside. Click here to read my ...